Author:
Thomas L.,Grempler R.,Eckhardt M.,Himmelsbach F.,Sauer A.,Klein T.,Eickelmann P.,Mark M.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference6 articles.
1. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.;Ghosh;J Clin Pharmacol,2011
2. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.;Bays;Curr Med Res Opin,2009
3. BI 10773, a novel and selective SGLT-2 inhibitor, lowers blood glucose and improves glycaemic control in diabetic rodent models.;Eickelmann;Diabetologia,2009
4. Empagliflozin, a novel, selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.;Grempler;Diabetes Obes Metab,2011
5. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.;Han;Diabetes,2008
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献